|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.935 USD | +2.98% |
|
+1.74% | +195.21% |
| 18/04 | JonesTrading Starts Rezolute With Buy Rating, $10 Price Target | MT |
| 06/03 | Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia | CI |
Rezolute, Inc. reported earnings results for the first quarter ended September 30, 2023. For the first quarter, the company reported net loss was USD 14.52 million compared to USD 9.83 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.19 a year ago.
Diluted loss per share from continuing operations was USD 0.28 compared to USD 0.19 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +195.21% | 114M | |
| +4.54% | 111B | |
| +11.14% | 105B | |
| -12.28% | 22.34B | |
| -3.76% | 21.93B | |
| -6.17% | 18.59B | |
| -35.21% | 18.12B | |
| -9.38% | 16.96B | |
| +3.01% | 13.7B | |
| +36.28% | 12.45B |
REZOLUTE, INC. 